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The blood-brain barrier (BBB) plays an important role in the pathophysiology of central nervous system (CNS) disorders such as stroke and hypoxic-ischemic brain injury. Vascular endothelial growth factor (VEGF) is involved in angiogenesis and vasogenic edema during stroke and hypoxia. However, the role of VEGF in BBB permeability after hypoxia has not been fully elucidated. We therefore investigated VEGF effects in an in vitro BBB model using rbcec4 endothelial cell line with the stimulation of VEGF or hypoxia. In this study, BBB permeability was studied using 14 C-sucrose detection. The expression of BBB tight junction protein ZO-1, and the expression and phosphorylation of vasodilator stimulated phosphoprotein (VASP), VEGF and VEGF receptor 2 (VEGFR2) were determined using fluorescent immunocytochemistry and western blot analyses. We found that hypoxia upregulated VEGF expression, and VEGF increased BBB permeability. Hypoxia also increased VASP phosphorylation, which was mediated, in part, through VEGFR2. We also found that VASP at tight junctions was co-localized with ZO-1 in cell-cell contacts. Our findings show that VASP phosphorylation is affected by hypoxia and VEGFR2 inhibition suggesting a role for VASP in BBB permeability.
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The blood-brain barrier (BBB) plays an important role in the pathophysiology of central nervous system (CNS) disorders such as hypoxia, hypoxia-ischemia, and stroke. Increased BBB permeability after CNS disorders can lead to cerebral edema resulting in an exacerbation of injury (Stamatovic et al., 2008) . BBB permeability can be changed in response to a variety of stimulators or stressors. These molecular stimulators, including vascular endothelial growth factor (VEGF), can exert beneficial or deleterious effects on the brain, depending on the context, timing, and functional cellular outcomes of signaling (Roux and Couraud, 2005) . Early after stroke, VEGF signaling increases paracellular permeability of endothelial Abbreviations: BBB, blood-brain barrier; CNS, central nervous system; VEGF, vascular endothelial growth factor; VEGFR2, VEGF receptor 2; VASP, vasodilator stimulated phosphoprotein; ZO-1, zonula occludens 1; cGMP, cyclic guanosine monophosphate; PKA, protein kinase A; PKG, cGMP-dependent protein kinase; AMPK, AMP-activated protein kinase; PI3K, phosphatidylinositol-3-kinase; PBS, phosphate buffered saline; TEER, trans-endothelial electrical resistance; DIV, day in vitro; DMEM, dulbecco's modified eagle's medium.cells, which causes vasogenic edema and contributes to cerebral swelling (Abumiya et al., 2005) . At later points, VEGF signaling initiates the formation of new cerebral blood vessels (Wang et al., 2007) . Studies that examine whether VEGF has beneficial or deleterious roles following cerebral stroke provide mixed results.
The controversial effects of exogenous VEGF on brain ischemia or stroke may be due to the timing and route of VEGF administration. One study which looked specifically at the timing of VEGF administration by intravenous infusion following stroke illustrated that early VEGF administration at 1 h after stroke increased BBB leakage. Conversely, delayed VEGF administration at 48 h after stroke enhanced angiogenesis and improved neurological outcome (Zhang et al., 2000) . Another study suggested that the beneficial effects of intracerebroventricular administration of VEGF following stroke were associated with activation of the PI3K-Akt pathway without increasing BBB permeability and angiogenesis (Kaya et al., 2005) . Early intravenous VEGF administration in the same study was deleterious and increased infarct volume (Kaya et al., 2005) .
In vitro studies further reveal consequences of the route of VEGF intervention. Studies utilizing in vitro BBB models containing endothelial monolayers which are in contact with media from separate apical and basolateral compartments demonstrate an ability of VEGF to increase BBB monolayer permeability in a directional 0736-5748/$36.00 © 2010 ISDN. Published by Elsevier Ltd. All rights reserved. doi:10.1016/j.ijdevneu.2010.06.010
